Increased Risk of Relapse for ALL Patients Living in Extreme Poverty
Among children receiving maintenance therapy for ALL, those living in extreme poverty had a nearly 2-fold greater risk of relapse than those not living in extreme poverty.
Among children receiving maintenance therapy for ALL, those living in extreme poverty had a nearly 2-fold greater risk of relapse than those not living in extreme poverty.
For patients with acute lymphoblastic leukemia treated on pediatric regimens, overweight or obese BMI is associated with worse outcomes.
Updated phase 3 data support sorafenib maintenance after allogeneic transplant as standard care for patients with FLT3-ITD AML, according to researchers.
Blincyto is supplied as a 35 mcg strength lyophilized powder for intravenous infusion after reconstitution.
Studies of CAR T-cell therapies presented at ASCO 2023 broke new ground and may change practice, according to researchers.
A phase 3 trial suggests that ponatinib is more effective than imatinib for patients with newly diagnosed Ph+ acute lymphoblastic leukemia.
Obecabtagene autoleucel produced a high response rate in adults with relapsed/refractory B-ALL in a phase 2 study.
Adult survivors of childhood cancer have an elevated risk of late-onset memory impairment, a study suggests.
The combination of blinatumomab and chemotherapy appears safe and effective in infants with KMT2A-rearranged ALL, according to researchers.
Living along the Texas-Mexico border is associated with worse survival in children diagnosed with acute lymphoblastic leukemia.